Sökning: onr:"swepub:oai:DiVA.org:oru-113766" >
Use of beta-blocker...
-
Strell, CarinaDepartment of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden; Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway
(författare)
Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence : a Swedish retrospective cohort study
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
Springer-Verlag New York,2024
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-113766
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-113766URI
-
https://doi.org/10.1007/s10549-024-07358-yDOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-225016URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:158254620URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies:Uppsala UniversitySwedish Cancer SocietySwedish research CouncilTrond Mohn Foundation
-
BACKGROUND: Retrospective observational studies suggest a potential role of beta-blockers as a protective strategy against progression and metastasis in invasive breast cancer. In this context, we investigated the impact of beta-blocker exposure on risk for progression to invasive breast cancer after diagnosis of ductal cancer in situ (DCIS).METHODS: The retrospective study population included 2535 women diagnosed with pure DCIS between 2006 and2012 in three healthcare regions in SwedenExposure to beta-blocker was quantified using a time-varying percentage of days with medication available. The absolute risk was quantified using cumulative incidence functions and cox models were applied to quantify the association between beta-blocker exposure and time from DCIS diagnosis to invasive breast cancer, accounting for delayed effects, competing risks and pre-specified confounders.RESULTS: The median follow-up was 8.7 years. One third of the patients in our cohort were exposed to beta-blockers post DCIS diagnosis. During the study period, 48 patients experienced an invasive recurrence, giving a cumulative incidence of invasive breast cancer progression of 1.8% at five years. The cumulative exposure to beta-blocker was associated with a reduced risk in a dose-dependent manner, though the effect was not statistically significant.CONCLUSION: Our observational study is suggestive of a protective effect of beta-blockers against invasive breast cancer after primary DCIS diagnosis. These results provide rationales for experimental and clinical follow-up studies in carefully selected DCIS groups.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Smith, Daniel,1981-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden(Swepub:oru)dlsh
(författare)
-
Valachis, Antonis,1984-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden(Swepub:oru)asvs
(författare)
-
Woldeyesus, HellénDepartment of Oncology, Uppsala University Hospital, Uppsala, Sweden
(författare)
-
Wadsten, CharlottaUmeå universitet,Kirurgi,Department of Surgery, Sundsvall Hospital, Sundsvall, Sweden(Swepub:umu)chwa0052
(författare)
-
Micke, PatrickDepartment of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden
(författare)
-
Fredriksson, IrmaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Breast, Endocrine Tumors and Sarcoma, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden
(författare)
-
Schiza, AglaiaDepartment of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
(författare)
-
Department of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden; Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, NorwayInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Breast Cancer Research and Treatment: Springer-Verlag New York207:2, s. 293-2990167-68061573-7217
Internetlänk
Hitta via bibliotek
Till lärosätets databas